Tapentadol for Multimodal Pain Management

Journal of Perianesthesia Nursing

Volumn 26, Issue 5, 2011, Pages 343-346

  Pasero, Chris ^a  

^a Clinical Consultant   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYLPROPYL)PHENOL; ANALGESIC AGENT; MU OPIATE RECEPTOR; PHENOL DERIVATIVE; TAPENTADOL;

ARTICLE; DRUG POTENTIATION; HUMAN; PAIN;

ANALGESICS; HUMANS; PAIN; PHENOLS; RECEPTORS, OPIOID, MU;

EID: 80053064473     PISSN: 10899472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jopan.2011.06.001     Document Type: Article

References (34)

1. Pasero C., Portenoy R.K. Neurophysiology of pain and analgesia and the pathophysiology of neuropathic pain. Pain Assessment and Pharmacologic Management 2011, 1-12. Mosby/Elsevier, St Louis, MO. C. Pasero, M. McCaffery (Eds.).
2. Veves A., Backonja M., Malik R.A. Painful diabetic neuropathy: Epidemiology, natural history, early diagnosis, and treatment options. Pain Med 2008, 9:660-674.
3. Pasero C., Polomano R.C., Portenoy R.K., et al. Adjuvant analgesics. Pain Assessment and Pharmacologic Management 2011, 623-818. Mosby/Elsevier, St Louis, MO. C. Pasero, M. McCaffery (Eds.).
4. Schroder W., Tzschentke T.M., Terlinden R., et al. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. J Pharmacol Exp Ther 2011, 337:312-320.
5. Afilalo M., Stegmann J.U., Upmalis D. Tapentadol immediate release: A new treatment option for acute pain management. J Pain Res 2010, 3:1-9.
6. Kress H.G. Tapentadol and its two mechanisms of action: Is there a new pharmacological class of centrally-acting analgesics on the horizon?. Eur J Pain 2010, 14:781-783. [editorial].
7. Terlinden R., Ossig J., Fliegert F., et al. Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. Eur J Drug Metab Pharmacokinet 2007, 32:163-169.
8. Tzschentke T.M., De Vry J., Terlinden R., et al. Tapentadol hydrochloride. Drugs Fut 2006, 31:1053-1061.
9. Pasero C., Quinn T.E., Portenoy R.K., et al. Opioid analgesics. Pain Assessment and Pharmacologic Management 2011, 277-622. Mosby/Elsevier, St Louis, MO. C. Pasero, M. McCaffery (Eds.).
10. Pricara Nucynta [package insert]. Pricara, Division of Ortho McNeil Pharmaceuticals 2009, Ortho-McNeil-Janssen, Raritan, NJ, Available at:, Accessed June 10, 2011. http://www.nucynta.com/nucynta/assets/Nucynta-PI.pdf.
11. Etropolski M., Kelly K., Okamoto A., et al. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. Adv Ther 2011, 28:401-417.
12. Kwong W.J., Ozer-Stillman I., Miller J.D., et al. Cost-effectiveness analysis of tapentadol immediate release for treatment of acute pain. Clin Ther 2010, 32:1768-1781.
13. American Society of Anesthesiologists (ASA) Practice guidelines for acute pain management in the perioperative setting: An updated report. Anesthesiology 2004, 100:1573-1581.
14. American Pain Society (APS) Principles of analgesic use in the treatment of acute and cancer pain 2008, APS, Glenview, IL. 6th ed.
15. Dworkin R.H., O'Connor A.B., Backonja M., et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007, 132:237-251.
16. Daniels S., Casson E., Stegmann J.U., et al. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr Med Res Opin 2009, 25:1551-1561.
17. Stegmann J.U., Weber H., Steup A., et al. The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery. Curr Med Res Opin 2008, 24:1385-1396.
18. Daniels S.E., Upmalis D., Okamoto A., et al. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin 2009, 25:765-776.
19. Kleinert R., Lange C., Steup A., et al. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: The results of a randomized, double-blind, placebo-controlled study. Anesth Analg 2008, 107:2048-2055.
20. Hersh E.V., Golubi S., Moore P.A. Analgesic update: Tapentadol hydrochloride. Compend Contin Educ Dent 2010, 31:594-599.
21. Candiotti K.A., Gitlin M.C. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: Tapentadol, a step toward a solution?. Curr Med Res Opin 2010, 26:1677-1684.
22. Vorsanger G., Xiang J., Okamoto A., et al. Evaluation of study discontinuations with tapentadol immediate release and oxycodone immediate release in patients with low back or osteoarthritis pain. J Opioid Manag 2010, 6:169-179.
23. Hartrick C., Van Hove I., Stegmann J.U., et al. Efficacy and tolerability of tapentadol immediate release and oxycodone HCL immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: A 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther 2009, 31:260-271.
24. Hale M., Upmalis D., Okamoto A., et al. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: A randomized, double-blind study. Curr Med Res Opin 2009, 25:1095-1104.
25. Wild J.E., Grond S., Kuperwasser B., et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract 2010, 10:416-427.
26. Etropolski M., Rauschkolb-Loffler C., Shapiro D., et al. A randomized, double-blind, placebo- and active-controlled phase III study of tapentadol ER for chronic low back pain: Analysis of efficacy endpoint sensitivity. J Pain 2009, 10(Suppl 4):S51. [abstract].
27. Afilalo M., Etropolski M.S., Kuperwasser B., et al. Efficacy and safety of tapentadol extended release compared with oxycodone release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: A randomized, double-blind, placebo- and active-controlled Phase III study. Clin Drug Investig 2010, 30:489-505.
28. Buynak R., Shapiro D.Y., Okamoto A., et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: Results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother 2010, 11:1787-1804.
29. Schwartz S., Etropolski M., Shapiro D.Y., et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: Results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin 2011, 27:151-162.
30. Kneip C., Terlinden R., Beier H., et al. Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett 2008, 2:67-75.
31. Oh C., Rengelshausen J., Mangold B., et al. A thorough QT/QTc study of multiple doses of tapentadol immediate release in healthy subjects. Int J Clin Pharmacol Ther 2010, 48:678-687.
32. Xu X.S., Smith J.W., Lin R., et al. Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain. Clin Pharmacokinet 2010, 49:671-682.
33. Smit J.W., Oh C., Rengelshausen J., et al. Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: Results of two randomized, open-label, crossover, drug-drug interaction studies. Pharmacotherapy 2010, 30:25-34.
34. Guay D. Is tapentadol an advance on tramadol?. Consult Pharm 2009, 24:833-840.